BIODESIX, INC. Research and Development Expense
BIODESIX, INC. (BDSX) reported Research and Development Expense of $3.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- BIODESIX, INC. research and development expense for the quarter ending 2026-06-30 was $3.13M, a 4.10% decline year-over-year.
- BIODESIX, INC. research and development expense for the quarter ending 2026-03-31 was $3.29M, a 14.46% increase year-over-year.
- BIODESIX, INC. research and development expense for the quarter ending 2025-12-31 was $2.87M, a 18.89% increase year-over-year.
- BIODESIX, INC. research and development expense for the quarter ending 2025-09-30 was $2.99M, a 17.47% increase year-over-year.
- BIODESIX, INC. research and development expense for fiscal 2025 was $12.00M, a 25.55% increase from fiscal 2024.
- BIODESIX, INC. research and development expense for fiscal 2024 was $9.56M, a 4.30% decline from fiscal 2023.
- BIODESIX, INC. research and development expense for fiscal 2023 was $9.99M, a 23.77% decline from fiscal 2022.
- BIODESIX, INC. research and development expense for fiscal 2022 was $13.10M, a 2.45% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.13M 10-Q · filed 2026-08-05 | $6.42M 10-Q · filed 2026-08-05 | $9.29M derived: sum of 3 quarters · filed 2026-08-05 | $12.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.29M 10-Q · filed 2026-05-04 | $6.16M derived: sum of 2 quarters · filed 2026-05-04 | $9.15M derived: sum of 3 quarters · filed 2026-05-04 | $12.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.86M derived: sum of 2 quarters · filed 2026-02-26 | $9.13M derived: sum of 3 quarters · filed 2026-08-05 | $12.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.99M 10-Q · filed 2025-11-03 | $6.26M derived: sum of 2 quarters · filed 2026-08-05 | $9.13M 10-Q · filed 2025-11-03 | $11.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.27M 10-Q · filed 2026-08-05 | $6.14M 10-Q · filed 2026-08-05 | $8.55M derived: sum of 3 quarters · filed 2026-08-05 | $11.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.87M 10-Q · filed 2026-05-04 | $5.28M derived: sum of 2 quarters · filed 2026-05-04 | $7.83M derived: sum of 3 quarters · filed 2026-05-04 | $10.39M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.96M derived: sum of 2 quarters · filed 2026-02-26 | $7.52M derived: sum of 3 quarters · filed 2026-02-26 | $9.56M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.55M 10-Q · filed 2025-11-03 | $5.11M derived: sum of 2 quarters · filed 2025-11-03 | $7.14M 10-Q · filed 2025-11-03 | $9.03M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $2.56M 10-Q · filed 2025-08-07 | $4.60M 10-Q · filed 2025-08-07 | $6.49M derived: sum of 3 quarters · filed 2025-08-07 | $8.43M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.04M 10-Q · filed 2025-05-13 | $3.93M derived: sum of 2 quarters · filed 2025-05-13 | $5.87M derived: sum of 3 quarters · filed 2025-05-13 | $8.78M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $3.83M derived: sum of 2 quarters · filed 2025-03-03 | $6.74M derived: sum of 3 quarters · filed 2025-03-03 | $9.99M 10-K · filed 2025-03-03 |
| 2023-09-30 | $1.94M 10-Q · filed 2024-11-01 | $4.85M derived: sum of 2 quarters · filed 2024-11-01 | $8.10M 10-Q · filed 2024-11-01 | $11.66M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $2.91M 10-Q · filed 2024-08-07 | $6.16M 10-Q · filed 2024-08-07 | $9.73M derived: sum of 3 quarters · filed 2024-08-07 | $12.70M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $3.25M 10-Q · filed 2024-05-08 | $6.82M derived: sum of 2 quarters · filed 2024-05-08 | $9.79M derived: sum of 3 quarters · filed 2024-05-08 | $13.15M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $6.54M derived: sum of 2 quarters · filed 2024-03-01 | $9.90M derived: sum of 3 quarters · filed 2024-03-01 | $13.10M 10-K · filed 2024-03-01 |
| 2022-09-30 | $2.97M 10-Q · filed 2023-11-07 | $6.33M derived: sum of 2 quarters · filed 2023-11-07 | $9.54M 10-Q · filed 2023-11-07 | $12.39M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $3.36M 10-Q · filed 2023-08-07 | $6.57M 10-Q · filed 2023-08-07 | $9.42M derived: sum of 3 quarters · filed 2023-08-07 | $12.71M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $3.21M 10-Q · filed 2023-05-11 | $6.06M derived: sum of 2 quarters · filed 2023-05-11 | $9.35M derived: sum of 3 quarters · filed 2023-05-11 | $12.67M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $6.14M derived: sum of 2 quarters · filed 2023-03-06 | $9.47M derived: sum of 3 quarters · filed 2023-03-06 | $12.79M 10-K · filed 2023-03-06 |
| 2021-09-30 | $3.29M 10-Q · filed 2022-11-03 | $6.62M derived: sum of 2 quarters · filed 2022-11-03 | $9.94M 10-Q · filed 2022-11-03 | $13.04M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $3.32M 10-Q · filed 2022-08-04 | $6.64M 10-Q · filed 2022-08-04 | $9.75M derived: sum of 3 quarters · filed 2022-08-04 | $12.46M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $3.32M 10-Q · filed 2022-05-11 | $6.43M derived: sum of 2 quarters · filed 2022-05-11 | $9.13M derived: sum of 3 quarters · filed 2022-05-11 | $11.24M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $5.81M derived: sum of 2 quarters · filed 2022-03-14 | $7.92M derived: sum of 3 quarters · filed 2022-03-14 | $10.82M 10-K · filed 2022-03-14 |
| 2020-09-30 | $2.71M 10-Q · filed 2021-11-15 | $4.81M derived: sum of 2 quarters · filed 2021-11-15 | $7.71M 10-Q · filed 2021-11-15 | $10.21M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $2.11M 10-Q · filed 2021-08-10 | $5.01M 10-Q · filed 2021-08-10 | $7.51M derived: sum of 3 quarters · filed 2021-08-10 | $9.87M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $2.90M 10-Q · filed 2021-05-11 | $5.40M derived: sum of 2 quarters · filed 2021-05-11 | $7.76M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $4.86M derived: sum of 2 quarters · filed 2021-03-16 | $10.47M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $2.36M 10-Q · filed 2020-12-10 | $7.97M 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |